Galapagos NV (GLPG.AS)
GLPG.AS on Amsterdam Stock Exchange
76.10EUR
25 Apr 2018
76.10EUR
25 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
€76.10
€76.10
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
466,553
466,553
52-wk High
€98.82
€98.82
52-wk Low
€61.88
€61.88
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
Name | Age | Since | Current Position |
---|---|---|---|
Rajesh Parekh |
2004 | Non-Executive Chairman of the Board | |
Onno van de Stolpe |
58 | 1999 | Chief Executive Officer, Executive Director, Member of the Executive Committee |
Bart Filius |
2017 | Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer | |
Piet Wigerinck |
2012 | Member of the Executive Committee, Chief Scientific Officer | |
Elizabeth Goodwin |
VP Corporate Communications & Investor Relations |
- BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros
- BRIEF-Galapagos NV Q1 Basic And Diluted Loss Per Share EUR 0.73
- BRIEF-Galapagos NV Creates New Warrant Plan
- UPDATE 2-FDA staff raises safety concerns over Lilly/Incyte arthritis drug
- Rising optimism on trade helps European shares higher as results come in